Panacea Biotec completes Phase I/II study of DengiAll, a tetravalent dengue vaccine candidate
The company has approached DGCI to seek accelerated review of its data to bring DengiAIl to market quickly
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.